Nephrodite
Private Company
Funding information not available
Overview
Nephrodite is a private, pre-revenue biotech company developing Holly™, an investigational implantable dialysis system. The device has received FDA Breakthrough Device Designation, recognizing its potential to address a major unmet need in treating end-stage kidney disease. The company's mission is to move beyond 70-year-old dialysis technology by offering a portable, continuous hemofiltration solution that could significantly improve patient quality of life and reduce systemic healthcare costs. Founded in 2017 and led by a physician-founder, Nephrodite is positioned to disrupt the large but stagnant renal care market.
Technology Platform
Implantable continuous hemofiltration platform utilizing a proprietary membrane and edge computing, designed for portable, at-home blood purification. Platform architecture is applicable to kidney, liver, and metabolic toxin management.
Opportunities
Risk Factors
Competitive Landscape
Nephrodite's primary competition is the entrenched standard of care: conventional in-center hemodialysis and home peritoneal dialysis, offered by large dialysis organizations (Fresenius, DaVita). It also competes with companies developing wearable artificial kidneys (e.g., Wearable Artificial Kidney project) and bioartificial kidneys (e.g., The Kidney Project). Nephrodite's fully implantable, continuous approach is a unique and potentially disruptive differentiator.